Merck & Co. Inc. stock (US58933Y1055): FDA nod for Winrevair reshapes growth story

Merck & Co. Inc. has secured a key US FDA approval for its rare disease drug Winrevair, adding a new growth pillar alongside cancer blockbuster Keytruda and vaccine franchise Gardasil.

Merck & Co. Inc. has received US Food and Drug Administration (FDA) approval for Winrevair (sotatercept-csrk) to treat adults with pulmonary arterial hypertension, expanding its portfolio beyond oncology and vaccines and reinforcing long?term growth prospects, according to Merck press release as of 03/22/2024 and Reuters as of 03/25/2024.

As of: 24.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals, healthcare
• Headquarters/country: Rahway, New Jersey, United States
• Core markets: Global prescription drugs, vaccines, animal health
• Key revenue drivers: Cancer drug Keytruda, HPV vaccine Gardasil, vaccines and hospital acute care portfolio
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co. Inc.: core business model

Merck & Co. Inc. is a large US pharmaceutical group focused on prescription medicines, vaccines and animal health products. The company generates most of its human health revenue from oncology, particularly immune?oncology therapies, and from a portfolio of vaccines used worldwide to prevent infectious diseases.

Keytruda, Merck’s programmed death receptor?1 (PD?1) inhibitor, remains the core growth engine. The drug is approved across multiple cancer indications, including lung, melanoma and other tumor types, and has steadily expanded its label over recent years, according to Merck press release as of 05/23/2024. This breadth underpins Merck’s strategy of leveraging oncology science across a wide patient base.

Alongside oncology, vaccines form a second major pillar. Gardasil, Merck’s vaccine to help prevent certain HPV?related cancers, has become a significant franchise as more countries adopt vaccination programs. The company also offers pediatric, adolescent and adult vaccines targeting diseases such as measles, mumps, rubella, shingles and others, building recurring demand patterns that complement the more cyclical oncology market.

Merck also operates an animal health division providing vaccines, antiparasitic products and technology solutions for livestock and companion animals. This business offers diversification and exposure to global protein and pet care markets, which can behave differently from human pharmaceutical cycles. For US investors, the combination of oncology, vaccines and animal health creates a diversified but still innovation?driven revenue mix.

Main revenue and product drivers for Merck & Co. Inc.

Keytruda remains at the center of investor focus because it accounts for a substantial share of Merck’s human health revenue. In 2023, Keytruda generated strong double?digit sales growth and continued to expand across earlier?stage cancer settings, according to Merck’s 2023 annual report published in February 2024. The company is investing heavily in trials that test Keytruda in adjuvant and neoadjuvant uses, which could support longer treatment durations.

Gardasil and Gardasil 9 make up another growth driver. Demand has been supported by catch?up vaccination campaigns following pandemic disruptions and by increasing awareness of HPV?related cancer prevention. In its first?quarter 2024 earnings report released in late April 2024, Merck highlighted continued momentum of the Gardasil franchise as a key contributor to vaccine segment growth, according to Merck press release as of 04/25/2024.

The newly approved Winrevair adds a rare disease revenue stream that is less exposed to generic competition in the near term. The FDA cleared the drug for adults with pulmonary arterial hypertension, a serious and progressive condition with limited treatment options, based on data showing improvement in exercise capacity and disease markers, according to Merck press release as of 03/22/2024. Rare disease products can support premium pricing and targeted commercialization strategies.

Beyond these flagship products, Merck’s hospital acute care and cardiometabolic portfolios also contribute to revenue, though growth rates differ by product and indication. The company has pursued business development, including acquisitions and licensing deals, to bolster its pipeline in oncology, immunology and cardiovascular disease. For US investors, the balance between Keytruda’s current strength and the need to build successors is an important strategic consideration, especially with key patent protections expiring later in the decade.

Conclusion

The recent US FDA approval of Winrevair broadens Merck & Co. Inc.’s portfolio and adds a rare disease component alongside major franchises such as Keytruda and Gardasil. Earnings updates through 2024 have underscored the importance of oncology and vaccines, while also highlighting management’s focus on pipeline and business development to address future patent expirations. For US investors, Merck represents a large-cap pharmaceutical player with meaningful exposure to the domestic healthcare system, a strong presence on the New York Stock Exchange and a mix of established blockbusters and emerging assets that together shape its medium?term risk and opportunity profile.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.